$AROC

Archrock (AROC) Q2 2026 Earnings Call Transcript

Archrock (AROC) reported Q2 2026 adjusted EBITDA of $213 million and adjusted EPS of $0.38. Contract operations revenue rose to $329 million, with adjusted gross margin at 71% and horsepower utilization at 94.4%. Aftermarket services revenue fell to $42 million. Adjusted free cash flow was $67 million, with $39 million returned via dividends. Full-year 2026 adjusted EBITDA guidance was narrowed to $865 million to $885 million.

Original reporting
Published Aug 12, 2026, 4:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 5:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Archrock (AROC) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$AROCNeutralMed
01

Why it matters

The most tradable elements are the narrowed 2026 adjusted EBITDA guidance, the dividend increase, leverage improvement, and the stated drivers of aftermarket deferrals and lube oil cost pressure.

02

Market read

Investors get a quantified update on earnings power (Q2 adjusted EPS, contract margins), full-year guidance, and capital returns, with explicit risk drivers tied to costs and customer maintenance timing.

03

What to watch

Caterpillar lead times extending to 2029 delivery and maintenance deferrals may create timing mismatches in revenue and cash flow that investors could re-rate beyond the stated guidance range.

Relevance 8/10Novelty 7/10Timing: today’s earnings call transcript, pre-market context for the Aug. 12 session

Background

Archrock’s Q2 2026 call covers contract operations performance, aftermarket services softness, capital allocation, and a 2027-2030 horsepower growth framework.

Company-level read

Ticker impact

$AROCNeutralMedium confidence
Context

Archrock guided 2026 adjusted EBITDA to $865M-$885M and reported Q2 adjusted EPS of $0.38, plus a 10% dividend increase to $0.23.

Expected impact

Near-term bias modestly positive if investors focus on margin resilience and capital returns, but tempered by the guidance headwind.

Evidence & confidence

The article provides multiple decision-relevant datapoints: Q2 results, full-year guidance range change, leverage/liquidity, and explicit dividend/shareholder return details. However, it is a transcript summary without consensus context, limiting precision on how the market will react.

Market effects

Highlights demand sensitivity in compression equipment and aftermarket maintenance to crude oil and lube oil cost dynamics, relevant to energy infrastructure operators.

Permian takeaway capacity and gas-to-oil ratio assumptions reinforce ongoing basin-level compression intensity expectations into 2027-2030.

LNG demand growth assumptions (to 35 Bcf/day by 2030) support longer-duration demand visibility for compression horsepower providers.

Counterpoint

The aftermarket services decline from $65M to $42M and guidance narrowing could signal demand softness that margin strength alone may not offset.

Key entities

  • Archrock

    Compression equipment and related services provider; reported Q2 2026 results and narrowed full-year adjusted EBITDA guidance.

  • Brad Childers

    CEO who attributed guidance pressure to lube oil cost pressure and aftermarket maintenance deferrals.

  • Mohit Singh

    CFO who discussed reinvestment priorities and demand outlook assumptions.

Related articles

$AROCMedAI 8/10

Archrock Miss Q2 Earnings & Revenues Estimates on AMS Weakness

Archrock (AROC) reported Q2 2026 adjusted EPS of 38 cents, missing the Zacks Consensus by 17.4%, and revenue of $371.2 million, below the $390.4 million estimate. The shortfall was attributed to weaker aftermarket services (AMS) versus resilient contract operations. Archrock raised its dividend to 23 cents and tightened 2026 adjusted EBITDA guidance to $865-$885 million.

$AROCMed

Archrock, Inc. (AROC): Results of Operations and Financial Condition

Archrock, Inc. (AROC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 aroc-20260804xex99d1.htm EX-99.1 Exhibit 99.1 ​ ​ ​ Archrock Reports Second Quarter 2026 Results ​ HOUSTON, August 4, 2026 - Archrock, Inc. (NYSE: AROC) (“Archrock” or the “Company”) today reported results for the second quarter 2026. Second Quarter 2026 Highlights ● Re

$ATROMedAI 8/10

Why Astronics Stock Popped Today

Astronics (NASDAQ: ATRO) shares rose about 15.8% by 11:30 a.m. ET after the company reported Q2 results above analyst expectations. Analysts forecast EPS of $0.54 on $245.8M sales; Astronics posted $0.70 EPS on $260M sales. The firm guided Q3 sales to $265M-$275M and cited $780.6M backlog.

$KMDAMed

Kamada Ltd. Q2 2026 Earnings Call Summary

Kamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.

$LITEHighAI 9/10

Lumentum Rockets 15% on Blowout Earnings, Coherent Climbs 9%, Corning Gains 5% on Optics Earnings and CoreWeave, Super Micro Read-Through

Lumentum (LITE) shares rose about 15% after fiscal Q4 2026 revenue more than doubled to $1.01B, non-GAAP EPS was $3.23, and guidance for fiscal Q1 2027 called for $1.225B to $1.275B revenue and $4.05 to $4.35 EPS. Coherent (COHR), Corning (GLW) and others gained on optics demand read-through. JPMorgan raised LITE target to $1,280; Bank of America cut to $1,000.

$ICCMMed

IceCure Medical Ltd Q2 2026 Earnings Call Summary

IceCure Medical reported Q2 2026 revenue up about 45%, driven by higher system sales and disposable probe use. Gross margin rose to 30% despite FX headwinds. U.S. footprint grew about 70% after FDA clearance. Management expects first CHOICE study patient enrollment in 3 to 4 weeks and 80 patients by March 2027. Cash was about $12M after a Q2 financing raising about $8.5M gross.